Acurx Pharmaceuticals Inc Stock Price, News & Analysis

Acurx Pharmaceuticals (NASDAQ: ACXP) reported significant findings regarding ibezapolstat, an antibiotic targeting C. difficile infections. Data from a recent trial showed that ibezapolstat preserves beneficial gut bacteria while effectively treating C. difficile infection (CDI). The Phase 2b trial is currently enrolling up to 64 patients to compare ibezapolstat's efficacy against vancomycin. Notably, ibezapolstat has received FDA QIDP and Fast Track Designations, emphasizing its potential importance in combating CDI.

Acurx Pharmaceuticals (NASDAQ: ACXP) announced its participation in the IDWeek 2022 Conference, presenting new data on ibezapolstat, an antibiotic targeting C. difficile infections (CDI). Key presentations include an oral update and a poster on ibezapolstat’s selective action against gut microbiota, emphasizing its clinical trial success. The Phase 2a trial showed 100% clinical cure rates in CDI patients. The company is currently enrolling in a Phase 2b trial comparing ibezapolstat to vancomycin.

Acurx Pharmaceuticals (NASDAQ: ACXP) reported financial and operational results for Q2 2022, highlighting ongoing enrollment in its Phase 2b clinical trial for C. difficile Infection (CDI) and the addition of clinical sites due to slower enrollment. The company raised $4.225 million from a registered direct offering and has $9.1 million in cash as of June 30, 2022. R&D expenses increased to $0.9 million, while G&A expenses decreased to $1.7 million. The net loss was $2.6 million, a reduction from $4.0 million in Q2 2021. A conference call is scheduled for August 16, 2022.

Acurx Pharmaceuticals (NASDAQ: ACXP) will release its Q2 2022 financial results on August 16, 2022, at 8:30 am ET. CEO David P. Luci and CFO Robert G. Shawah will host a call to discuss the results and provide a business update.

The company is developing Ibezapolstat, a new antibiotic targeting C. difficile infections, with promising Phase 2a trial results showing 100% clinical cure. Ibezapolstat has received FDA designations as a QIDP and Fast Track product.

Acurx Pharmaceuticals (NASDAQ: ACXP) presented new data on ibezapolstat at the 16th Biennial Congress of the Anaerobe Society of America. Findings from the Phase 2a trial showed 100% clinical and sustained cure rates in patients with Clostridioides difficile Infection (CDI). Ibezapolstat demonstrated favorable microbiome effects and outperformed vancomycin in in vitro tests. The company is advancing to a Phase 2b trial, increasing trial sites from 16 to 30 to expedite enrollment, aiming to further confirm ibezapolstat's anti-recurrence properties.

Acurx Pharmaceuticals (NASDAQ: ACXP) announced a registered direct offering of 1,289,980 shares at $3.25 per share, aggregating gross proceeds of approximately $4.225 million. The offering includes 130,769 pre-funded warrants sold to a U.S. institutional investor, with executives purchasing shares at $3.80. Series A and B unregistered warrants will also be issued to investors. Closing is anticipated around July 27, 2022, subject to customary conditions. The company intends to use net proceeds for general corporate purposes.

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) reported its financial results for Q1 2022, revealing a net loss of $2.7 million or $0.26 per share, up from a loss of $1.5 million or $0.21 per share in Q1 2021. R&D expenses rose to $0.8 million, compared to $0.1 million in the prior year, mainly due to Phase 2b trial costs. The company is advancing its Phase 2b trial for ibezapolstat targeting C. difficile, with enrollment expected to finish in late 2022. In addition, partnerships continue with Leiden University for further R&D.

Acurx Pharmaceuticals (NASDAQ: ACXP) will release its 2022 Q1 financial results on May 11, 2022, at 8:30 am ET. Following the results, a conference call will be held where CEO David P. Luci and CFO Robert G. Shawah will provide updates. The company is advancing its antibiotic ibezapolstat for treating C. difficile infections, with successful Phase 1 and 2a trials showing 100% clinical cure rates. Ibezapolstat has received FDA designations for streamlined development due to the urgent need for new treatments.

Acurx Pharmaceuticals (NASDAQ: ACXP) reported its financial and operational results for Q4 and full year 2021. The company is enrolling in a Phase 2b trial for its lead antibiotic, ibezapolstat, aimed at treating C. difficile infections. The trial compares ibezapolstat's efficacy against vancomycin. R&D expenses for the year decreased to $2.0 million, while general and administrative expenses rose significantly to $10.8 million, primarily due to stock-based compensation and increased professional fees. The net loss for 2021 was $12.7 million, with a loss per share of $(1.49).